VIKING THERAPEUT.DL -,005 WKN: A12GD6 ISIN: US92686J1060 Kürzel: VKTX Forum: Aktien Thema: Hauptdiskussion

Da bin ich gespannt wie tief das noch geht

jetzt wirds heftig

Sell the news

Die hast jetz wohl gewonnen

51,x€ freier Fall... das tut richtig weh ach man ey

52,x€ nur noch...

Das fällt ja immer mehr 🙄

Hab bei 53 mal eine Order gesetzt

Wenns nur das wäre. Die Grenze seit Februar ist gerissen, ist mir glaube ich auch zu unsicherr gerade. Das bei guten Nachrichten, bei Viking man oh man

OK jetzt gibts SL Rallye

Sind jetzt sogar rot, ob da heute noch was Großes kommt? Mhh. Keine Ahnung, aber es droht eine heftige Enttäuschung

Also ich war kurz davor einzusteigen. Habe mich dann aber daran erinnert, dass jede positive Nachricht an der Börse mit fallenden Kurse quittiert wird. Entsprechend Glück gehabt. Bei 45€ bin ich wieder dabei :-P

wow lol

Ganzer Anstieg verpufft, verstehe ich nicht... naja hm

Mich juckts auch in den Fingern, aber ich stecke mit 215 Anteilen schon sehr tief drin

$VKTX NOICE: Viking Therapeutics' VK2809 shows efficacy in Phase 2b NASH study Viking Therapeutics announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis - NASH -. The study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo. Results highlight achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809. On the secondary endpoint of NASH resolution with no worsening of fibrosis, VK2809-treated patients demonstrated NASH resolution ranging from 63% to 75%, vs. 29% for placebo. Across the combined VK2809 treatment groups, 69% achieved NASH resolution. On the secondary endpoint evaluating improvement in fibrosis with no worsening of NASH, VK2809-treated patients demonstrated improvement in fibrosis ranging from 44% to 57% vs. 34% for placebo. Across the combined VK2809 treatment groups, 51% achieved improvement in fibrosis with no worsening of NASH. On the secondary endpoint evaluating the proportion of patients experiencing both resolution of NASH and improvement in fibrosis, VK2809-treated patients demonstrated improvement ranging from 40% to 50% vs. 20% for placebo. Across the combined VK2809 treatment groups, 44% achieved this endpoint. Study results were consistent under various sensitivity analyses. Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, which was the primary endpoint in VOYAGE. Patients receiving VK2809 continued to demonstrate statistically significant reductions in liver fat content at Week 52. Patients receiving VK2809 demonstrated placebo-adjusted reductions in LDL-C ranging from 20% to 25%, as well as reductions in triglycerides and atherogenic proteins and apolipoprotein C-III, all of which have been correlated with cardiovascular risk. VK2809 demonstrated encouraging safety and tolerability in this study through 52 weeks of treatment, with minimal differences compared with the previously reported results at 12 weeks. 94% of treatment related adverse events among patients receiving VK2809 were reported as mild or moderate.